22157.jpg
Outlook on the Osteoarthritis Global Market (IA Injections, NSAIDs & Analgesics) to 2025 - Inclining Occurrence of Osteoarthritis is Driving Growth
June 28, 2021 04:48 ET | Research and Markets
Dublin, June 28, 2021 (GLOBE NEWSWIRE) -- The "Global Osteoarthritis Market (IA Injections, NSAIDs & Analgesics): Insights, Trends & Forecast (2021-2025)" report has been added to...
22157.jpg
GCC Generic Injectables Market: Strong Growth Expected from 2021-2026
June 09, 2021 09:39 ET | Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "GCC Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
22157.jpg
Worldwide Intravenous Solutions Industry to 2026 - Featuring Ajinomoto, Baxter International and Grifols Among Others
May 27, 2021 08:38 ET | Research and Markets
Dublin, May 27, 2021 (GLOBE NEWSWIRE) -- The "Intravenous Solutions Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Graphical Research.jpg
Compounding Pharmacies Market Trends - Growth Forecasts 2026 | COVID-19 Impact Analysis: Graphical Research
February 16, 2021 05:00 ET | Graphical Research
Pune, India, Feb. 16, 2021 (GLOBE NEWSWIRE) -- The global compounding pharmacies market size is anticipated to register substantial growth rate during the forecast period owing to growing...
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
January 06, 2016 08:00 ET | SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
January 05, 2016 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed to Participate in Upcoming Investor Conferences
September 02, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results
August 06, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Appoints David W. Nassif as Its Full Time Executive Vice President and Chief Financial Officer
April 08, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company, today announced the appointment of David W. Nassif as its full time Executive...